Johns Hopkins Medicine: Researchers Id Biomarkers of Response to Immunotherapy for Kidney Cancer
April 07, 2023
April 07, 2023
BALTIMORE, Maryland, April 7 (TNSjou) -- Johns Hopkins Medicine issued the following news release:
The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict -- before treatment begins -- how well patients with kidney cancer will respond to immunotherapy, according to new research directed by investigators at the Johns Hopkins Kimmel Cancer Center and its . . .
The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict -- before treatment begins -- how well patients with kidney cancer will respond to immunotherapy, according to new research directed by investigators at the Johns Hopkins Kimmel Cancer Center and its . . .